High-Altitude Polycythemia Study

NCT07600086 · tracked via the Priya Life Science China tracker

Sponsor

Tibet Autonomous Region People's Hospital

Phase

Not applicable

Started

2026-05

Last updated

2026-05-20

Condition(s) studied

High-altitude PolycythemiaHAPC

Investigational drug(s) / intervention(s)

Non-invasive ventilator

Non-invasive ventilator: Treatment with non-invasive ventilator (CPAP, BiPAP) in the intervention group.

Study summary

This study aims to evaluate the clinical efficacy of non-invasive ventilation (NIV) in treating patients with high-altitude polycythemia (HAPC).

Participants will be enrolled according to the international diagnostic criteria for high-altitude polycythemia. The study will use both retrospective cohort and prospective study methods.

All participants will receive standard basic care. In addition, the intervention group will receive non-invasive ventilation treatment using either BiPAP or CPAP mode.

Key measurements, including routine blood tests, liver function, renal function, uric acid, blood lipid profile, electrocardiogram and echocardiography, will be collected as primary and secondary outcome measures to assess the effects of the treatment.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Diagnosed with high-altitude polycythemia (HAPC). 2. Aged 18 years or older, with no gender restriction. 3. Voluntarily participate in the study and sign the informed consent form. Exclusion Criteria: 1. Disturbance of consciousness. 2. Inability to independently clear airway secretions, with the risk of aspiration. 3. Severe upper gastrointestinal bleeding. 4. Hemodynamic instability. 5. Upper airway obstruction. 6. Un drained pneumothorax or mediastinal emphysema. 7. Conditions that prevent mask wearing, such as facial trauma or deformity. 8. Patient non-compliance.

Primary outcome measure(s)

Change in Hemoglobin (Hb) Concentration — Baseline, 3 months, 6 months after treatment initiation
The primary endpoint is the absolute change in blood hemoglobin concentration (g/dL) from baseline to 3-month and 6-month follow-up. A reduction in hemoglobin level is defined as a clinically significant improvement in high altitude polycythemia status.

Trial sites (2)

Facility	City	Region	Status
People's Hospital of Xizang Autonomous Region；Lhasa, Xizang Autonomous Region, China, 850000	Xizang	China
Xizang Autonomous Region People's Hospital	Xizang	China

More Tibet Autonomous Region People's Hospital trials in China

Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and Application Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07600086 on ClinicalTrials.gov ↗ ← All trials in China